Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.17/2680
Registo completo
Campo DCValorIdioma
dc.contributor.authorGuerreiro Castro, S-
dc.contributor.authorIsenberg, D-
dc.date.accessioned2017-04-19T15:12:26Z-
dc.date.available2017-04-19T15:12:26Z-
dc.date.issued2017-03-
dc.identifier.citationTher Adv Musculoskelet Dis. 2017 Mar;9(3):75-85pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/2680-
dc.description.abstractSystemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentations, whose management presents many challenges. Many disease modifying or immunosuppressive drugs have been used with limited success, especially in patients with more severe disease activity. Belimumab is the first drug to be approved specifically for the treatment of SLE in more than 50 years. By blocking the B-cell activating factor, it interferes in B-cell differentiation and survival. Here we consider the results of the clinical trials that led to its approval, as well as the post-hoc analyses, follow-up studies and the current trials.pt_PT
dc.language.isoengpt_PT
dc.publisherSAGE Publicationspt_PT
dc.rightsopenAccesspt_PT
dc.subjectHCC MEDpt_PT
dc.subjectBelimumabpt_PT
dc.subjectBiologic Therapypt_PT
dc.subjectImmunosuppressive Agentspt_PT
dc.subjectSystemic Lupus Erythematosuspt_PT
dc.titleBelimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulnesspt_PT
dc.typearticlept_PT
dc.peerreviewedyespt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
degois.publication.firstPage75pt_PT
degois.publication.lastPage85pt_PT
degois.publication.issue3pt_PT
degois.publication.titleTherapeutic Advances in Musculoskeletal Diseasept_PT
degois.publication.volume9pt_PT
dc.identifier.doi10.1177/1759720X17690474pt_PT
Aparece nas colecções:MED - Artigos

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
Ther Adv Musculos Dis.pdf1,06 MBAdobe PDFVer/Abrir


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.